Verdict
TRUE
TRUE — The FDA approved Casgevy in December 2023 Is Real
Verified on August 8, 2026
The FDA officially approved Casgevy on December 8, 2023, as a gene therapy for sickle cell disease. FDA Approves First Gene Therapies to Treat Patients with Sickle Cell.
Confidence82%
How strongly independent, cited sources support this verdict.
Claim reviewed
The FDA approved Casgevy in December 2023.
Analysis summary
The FDA officially approved Casgevy on December 8, 2023, as a gene therapy for sickle cell disease. This milestone marked the first U.S. approval of a CRISPR-based treatment.
Evidence profile
59 / 100 weighted evidence score
H:2 / M:0 / L:1
Key findings
- FDA Approves First Gene Therapies to Treat Patients with Sickle Cell.
Sources
Analyzed across 2 independent publishers
FDA Approves First Gene Therapies to Treat Patients with Sickle Cell ...
Fda
High credibility
78/100
government_primaryInstitutional domain
Press Release - CRISPR Therapeutics
Crisprtx
Low credibility
24/100
unknown_low_authorityStandard web source
CASGEVY | FDA
Fda
High credibility
74/100
government_primaryInstitutional domain
Citations
Copy formatted citations from the verified sources above.
Need to verify another claim?
Open Claims Radar to analyze headlines, posts, or links with live source checks.
Verify a claim
Verified by
Claims Radar
Possum Mattern Studios
Possum Mattern Studios